# EDGAR Filing Document

**Accession Number:** 0001244191
**File Stem:** 0001193125-25-262869
**Filing Date:** 2025-11
**Character Count:** 15039
**Document Hash:** eaf0a42d919811895f9e6a245eb814e6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-262869.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001193125-25-262869

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Organogenesis Holdings Inc.
- **CENTRAL INDEX KEY:** 0001661181
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89667
- **FILM NUMBER:** 251445425

**BUSINESS ADDRESS:**
- **STREET 1:** 85 DAN ROAD
- **CITY:** CANTON
- **STATE:** MA
- **ZIP:** 02021
- **BUSINESS PHONE:** 781-575-0775

**MAIL ADDRESS:**
- **STREET 1:** 85 DAN ROAD
- **CITY:** CANTON
- **STATE:** MA
- **ZIP:** 02021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avista Healthcare Public Acquisition Corp.
- **DATE OF NAME CHANGE:** 20151215
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NUSSDORF GLENN H
- **CENTRAL INDEX KEY:** 0001244191

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** C/O ORGANOGENESIS HOLDINGS INC.
- **STREET 2:** 85 DAN ROAD
- **CITY:** CANTON
- **STATE:** MA
- **ZIP:** 02021

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 11)**

**Organogenesis Holdings Inc.**

*(Name of Issuer)*

**Class A Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**68621F102**

*(CUSIP Number)*

**Lori Freedman**<br>Organogenesis Holdings Inc.<br>85 Dan Road<br>Canton MA 02021<br>(781) 575-0775

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**05/14/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **68621F102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Glenn H. Nussdorf** | Name of reporting person<br>**Glenn H. Nussdorf** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**10994161.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1254399.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**10994161.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1254399.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12248560.00** | Aggregate amount beneficially owned by each reporting person<br>**12248560.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.7%** | Percent of class represented by amount in Row (11)<br>**9.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **68621F102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**GN 2016 Family Trust u/a/d August 12, 2016** | Name of reporting person<br>**GN 2016 Family Trust u/a/d August 12, 2016** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**918680.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**918680.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**918680.00** | Aggregate amount beneficially owned by each reporting person<br>**918680.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.7%** | Percent of class represented by amount in Row (11)<br>**0.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **68621F102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016** | Name of reporting person<br>**GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**7928570.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**7928570.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7928570.00** | Aggregate amount beneficially owned by each reporting person<br>**7928570.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.2%** | Percent of class represented by amount in Row (11)<br>**6.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Organogenesis Holdings Inc.

**(c) Address of Issuer's Principal Executive Offices:**
85 Dan Road, Canton, MA, 02021

This Amendment No. 11 (this "Amendment No. 11") amends and supplements the beneficial ownership statement on Schedule 13D originally filed on December 20, 2018, as amended by Amendment No. 1 to the statement on Schedule 13D filed on November 27, 2019, Amendment No. 2 to the statement on Schedule 13D filed on November 19, 2020, Amendment No. 3 to the statement on Schedule 13D filed on May 11, 2021, Amendment No. 4 to the statement on Schedule 13D filed on June 1, 2021, Amendment No. 5 to the statement on Schedule 13D filed on December 17, 2021, Amendment No. 6 to the statement on Schedule 13D filed on December 30, 2021, Amendment No. 7 to the statement on Schedule 13D filed on November 14, 2024, Amendment No. 8 to the statement on Schedule 13D filed on January 3, 2025, Amendment No. 9 to the statement on Schedule 13D filed on January 13, 2025, and Amendment No. 10 to the statement on Schedule 13D filed on June 26, 2025 (such Schedule 13D and amendments, the "Original Statement"), on behalf of Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom, Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust dated 12/20/12, Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016, GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, RED Holdings, LLC and Josette Ades (each, a "Group Member" and, collectively, the "Group"). The Original Statement, as amended by this Amendment No. 11 (the "Statement"), relates to shares of Class A common stock, par value $0.0001 per share (the "Shares"), of Organogenesis Holdings Inc., a Delaware corporation (the "Issuer").

Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Original Statement. This Amendment No. 11 supplements Item 3 and amends and restates Items 2 and 5(a)-(c), as set forth below. Except as set forth in this Amendment No. 11, all previous Items in the Original Statement remain unchanged.

As previously reported in the Original Statement, on June 24, 2025, the Group Members determined that, in light of the termination of the Controlling Stockholders' Agreement on March 10, 2025, and the expiration of the term of the directors last nominated and elected pursuant thereto at the Issuer's 2025 Annual Meeting of Stockholders, the Group Members no longer constitute a "group" within the meaning of Rule 13d-5 under the Act.

This Amendment No. 11 relates solely to Shares held by Mr. Nussdorf, the GN 2016 Family Trust u/a/d August 12, 2016 (the "GN Trust") and the GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (the "GN GRAT", together with the GN Trust, the "Trusts", and the Trusts, together with Mr. Nussdorf, the "Reporting Persons" and each a "Reporting Person").

**Item 5. Interest in Securities of the Issuer**

**(a)**
The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person's cover page to this Statement, are based on a total of 126,857,709 Shares, which reflects the number of Shares reported as outstanding on July 31, 2025, in the Quarterly Report on Form 10-Q filed by the Issuer on August 7, 2025. All of the Share numbers reported below, and on each Reporting Person's cover page to this Statement, are as of October 30, 2025. The cover page to this Statement for each Reporting Person is incorporated by reference in its entirety into this Item 5.

Glenn H. Nussdorf is the beneficial owner of a total of 12,248,560 Shares, representing approximately 9.7% of the outstanding Shares and consisting of (i) 3,065,591 Shares held by Mr. Nussdorf, (ii) 918,680 Shares held by the GN Trust, (iii) 7,928,570 Shares held by the GN GRAT and (iv) 335,719 Shares held by the Glenn Nussdorf 10  Year Follow On Trust Dated 11-1-1998 (the "GN Follow On Trust").

The GN Trust is the beneficial owner of a total of 918,680 Shares, representing approximately 0.7% of the outstanding Shares. The GN Trust holds all such Shares directly. Michael Katz is the trustee of the GN Trust.

The GN GRAT is the beneficial owner of a total of 7,928,570 Shares, representing approximately 6.2% of the outstanding Shares. The GN GRAT holds all such Shares directly. Mr. Nussdorf is the trustee of the GN GRAT.

The cover page to this Schedule 13D for each Reporting Person is incorporated by reference in its entirety into this Item 5.

**(b)**
Glenn H. Nussdorf exercises sole voting and dispositive power over the Shares held by him directly and the Shares held by the GN GRAT. Mr. Nussdorf exercises shared voting and dispositive power over the Shares held by the GN Trust and the GN Follow on Trust. Mr. Nussdorf disclaims beneficial ownership of the Shares held by the Trusts and the GN Follow on Trust, except to the extent of his pecuniary interest therein.

**(c)**
None of the Trusts nor Mr. Nussdorf have effected any transactions in Shares during the past 60 days. Notwithstanding the foregoing, on May 14, 2025, the GN Follow On Trust purchased 251,001 Shares at a weighted average price of $3.0878 per Share. These Shares were purchased in multiple transactions at prices ranging from $3.00 to $3.10, inclusive. On May 15, 2025, the GN Follow On Trust purchased 107,494 Shares at a weighted average price of $2.9862 per Share. These Shares were purchased in multiple transactions at prices ranging from $2.9725 to $3.00, inclusive. On June 9, 2025, the GN Follow On Trust sold 4,156 Shares at a weighted average price of $3.5003 per Share. These Shares were sold in multiple transactions at prices ranging from $3.50 to $3.505, inclusive. On June 10, 2025, the GN Follow On Trust sold 18,620 Shares at a weighted average price of $3.5583 per Share. These Shares were sold in multiple transactions at prices ranging from $3.55 to $3.59, inclusive.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Glenn H. Nussdorf

**Signature:** /s/ Glenn H. Nussdorf

**Name/Title:** Glenn H. Nussdorf

**Date:** 11/03/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** GN 2016 Family Trust u/a/d August 12, 2016

**Signature:** /s/ Michael W. Katz

**Name/Title:** Michael W. Katz, Trustee

**Date:** 11/03/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016

**Signature:** /s/ Michael W. Katz

**Name/Title:** Michael W. Katz, Trustee

**Date:** 11/03/2025